New drug cocktail shows promise against tough esophageal cancer
NCT ID NCT07312578
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced esophageal cancer. About 48 adults aged 18-70 with resectable tumors will be randomly assigned to receive the combination or standard chemo alone. The main goal is to see if the combination leads to a complete disappearance of the cancer at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of GI Oncology, Peking University Cancer Hospital,
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.